Serotonin Syndrome ascribed to Combined Selegeline and Amitriptiline: A Case Report with an Indonesian Parkinson Patient by Karina, Lidya & Cahyadi, Hanny
1 INTRODUCTION  
The serotonin syndrome is a life-threatening 
condition caused by increased serotonergic activity. 
(Boyer and Shannon, 2005) Three main symptom of 
serotonin syndrome are altered mental status, 
autonomic hyperactivity, and neuromuscular 
abnormalities (Table 1). Sign of serotonin syndrome 
vary in range, from mild cases such as tremor and 
diarrhea to delirium, neuromuscular rigidity, 
hypertension, tachycardia, and coma in severe cases 
(Abadie, Kaye and Kaye, 2013; Boyer and Shannon, 
2005) 
 
Table 1. Symptoms of Serotonine Syndrome 
  
Altered mental status Confusion, Hypomania, 
Hallucinations, Agitation, 
Slightly slurred speech, 
Headache, Delirium, Coma 
Automic hyperactivity Syncope, Shivering, 
Sweating, High fever, 
Hypertension, Tacycardia, 
Nausea, Diarrhea, Mydriasis 
Neuromuscular 
abnormalities 
Muscular rigidity, 
Myoclonus, Tremor 
 
 
The actual prevalence of serotonin syndrome is 
unknown. The number of unreported cases is greater 
than the reported cases. Serotonin Syndrome is often 
undiagnosed and it is attributed to be a general side 
effect of certain treatment. (Abadie, Kaye and Kaye, 
2013)  
 
It has been reported since 1950s that there is a risk of 
developing serotonin syndrome if a patient consumed 
‘combined treatment’ which both induced excess 
intra-synaptic serotonin or 5-hydroxytryptamine(5-
HT). (Gilman, 1999) Parkinson disease patient is one 
example of patient who use those treatment 
combinations. The typical motor disease with some 
characterize non-motor features such as depression 
lead the treatment of Parkinson disease patient into a 
combination of both MAO-inhibitor and 
antidepressant. It is known that the combination of 
MAO-inhibitor and antidepressant theoretically 
Serotonin Syndrome ascribed to Combined Selegeline and Amitriptiline: A Case Report with an Indonesian 
Parkinson patient 
L. Karina 
Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia 
H. Cahyadi 
Dept. of Pharmacy, National Hospital, Surabaya, Indonesia 
 
ABSTRACT:  
A-62-year-old man, diagnosed as Parkinson patient, reported to hospital B after having taking medication 
prescribed by two different doctors. Among his medication, it was found that he consumed both selegeline 5mg 
1 tablet and amitriptyline 25mg 0,5 tab at 07.00 AM and 01.00 PM. After three weeks consuming these 
medications, his movement stability at his left and right leg was deteriorated, felt confusion, tremor on his hand, 
restless leg and agitation. This case report aims to analyze the drug related problems. Medscape drug interaction 
checker and Naranjo scale was used to examine the drug related problems. Literature review from guideline 
and journal was performed to find out the reason of drug related problems. Significant interaction was found 
and known as the cause of increased brain serotonin level. Probable adverse drug reaction was demonstrated 
on Naranjo scale. In several cases reports, the condition was reported as serotonin syndrome. 
 
Keywords: Serotonin Syndrome, Parkinson, Selegiline, Amitriptiline 
increased the risk of serotonin syndrome when it is 
used concurrently. (Setter and Cerruto, 2010)   
In Indonesia, this combination is widely used in 
Parkinson disease patients. In contrary, serotonin 
syndrome has not been reported and the information 
related to this syndrome is quite rare. This case report 
aim to analyze the drug related problem and 
increasing the awareness of serotonin syndrome in 
Indonesian Parkinson disease patients.   
2 CASE PRESENTATION 
A-62-year-old man was diagnosed by doctor as 
Parkinson disease patient since December 2014. He 
was diagnosed abroad Indonesia, and was given 
Parkinson medication. After 1 year taken the 
medication, there was no improvement on his 
condition. Afterwards, he come to Hospital A in 
Indonesia to see neurologist. According to the patient 
wife’s information, the Indonesian neurologist told 
him to continue his medicine from the previous 
prescription and add some other medication to 
improve patient’s condition. The list of patient’s 
medication schedule was listed on Table 2. Among 
the medications, it is found that selegiline and 
amitriptyline was prescribed concurrently both at 
07.00 AM and 01.00 PM. 
 
The first 2 weeks after taking the medication, the 
patient’s condition is getting better. But after three 
weeks, his wife said his condition was worsen. There 
was a deterioration in his movement stability at both 
his left and right leg. The patient also complained 
about feeling confusion, tremor on his hand, restless 
leg and agitation. His wife come to hospital B, to get 
second opinion from another neurologist. The 
neurologist at hospital B asked clinical pharmacy to 
assess his husband medication.   
 
Table 2. Patient’s Medication Schedule 
3 METHODS  
To analyze the drug related problems. First, we input 
all medications taken by the patients to Medscape 
drug interaction checker. Next, literature review from 
guideline and journal was performed to find out the 
reason or information related to the interaction. After 
that, Naranjo scale was used to examine the class of 
adverse drug reaction related to interaction. Last, the 
result of this analyses was presented as a case report. 
4 RESULTS AND DISCUSSIONS 
Medscape drug interaction checker reported that there 
were four interactions found in the patient’s 
medication. The interactions summarized in Table 3. 
From the interactions, it was found that patient 
complains were similar with the effect of interaction 
number 1.  
 
Table 3. Drug Interaction Checker Results (Medscape drug 
interaction checker, 2017) 
 
N
o 
Drug  
Combination  
Type of  
Interaction 
Information 
1 Selegiline and 
Amitriptyline 
Contraindicate
d 
Concurrent use or 
use within 14 days 
of Selegiline and 
Amitriptyline the 
combination is 
contraindicated. 
Both medications 
can increase 
serotonin levels. 
2 Selegiline and 
Levodopa 
Contraindicate
d 
Selegiline and 
Levodopa is 
contraindicated 
because both has a 
pharmacodynamic
s synergism effect. 
It may increase the 
possibility of 
developing acute 
hypertension 
episode. 
Concominant 
therapy with 
selegiline and 
carbidopa-
levodopa is 
associated with 
severe orthostatic 
hypotension. 
Time Name of medicine Amount  
(tablets) 
Morning  
(07.00 am) 
Pramipexole 0.75 mg 
Carbidopa + Levodopa +  
Entacapone 100/125/200 
Selegiline 
Amitryptiline 25 mg 
1 
1 
 
1 
0.5 
Afternoon 
(01.00 pm) 
Carbidopa + Levodopa +  
Entacapone 100/125/200 
Selegiline 
Amitryptiline 25 mg 
1 
 
1 
0.5 
Evening  
(06.00 pm) 
Carbidopa + Levodopa +  
Entacapone 100/125/200 
Bromocriptine 2.5 mg 
1 
 
1 
3 Bromocriptin
e and 
Levodopa 
Monitor 
Closely 
Combination of 
Bromocriptine and 
Levodopa both 
increase dopamine 
effect. The 
combination is 
known to give 
therapeutic effect 
in Parkinson 
patient and may 
lower levodopa 
doses. Dosage 
should be carefully 
titrated during 
concomitant 
treatment and 
patients should be 
monitored closely. 
4 Levodopa and 
Pramipexole 
Monitor 
Closely 
Combination of 
levodopa and 
pramipexole 
increase 
dopaminergic 
effects 
 
Selegiline is used in Parkinson management in which 
levodopa/carbidopa therapy is deteriorating. 
Selegiline is categorized as anti-parkinson’s agent 
which inhibited monoamine oxidase activity (MAO 
inhibitor). Monoamine oxidase was known as an 
enzyme which is used in degradation of monoamine 
such as norepinephrine, dopamine and serotonin. 
(Dana, Fuller, Goldman, Golembiewski, Gonzales, 
Lowe, Snoke, 2013) In Parkinson disease, it is 
necessary to used MAO inhibitor to block the 
degradation of dopamine. Inhibition of MAO activity 
indirectly increases intra-synaptic serotonin level. 
MAO inhibitor can be classified according to its 
selectivity into three groups, they were Non-selective 
MAO inhibitor, MAO-A inhibitor, and MAO-B 
inhibitor. Selegiline is included in selective MAO-B 
inhibitor.  
 
Amitriptyline is indicated as antidepressant agent. It 
was categorized as tricyclic antidepressant (TCA). 
The mechanism of action of this drug was inhibiting 
the re-uptake of monoamines such as norepinephrine, 
dopamine and serotonin from intra-synaptic area to 
presynaptic. (Dana, Fuller, Goldman, Golembiewski, 
Gonzales, Lowe, Snoke, 2013) This medication is 
prescribed as a treatment to non-motor features 
symptom such as depression which also presented in 
Parkinson disease patients. Inhibition of serotonin 
reuptake from intra-synaptic mean that the level of 
intra-synaptic serotonin would be increased.  
 
The literature review concluded that combination of 
both selegiline and amitriptyline both had the same 
effect on intra-synaptic serotonin level. Richard, 
Kurlan, Tanner et al, 1997 stated that this 
combination was contraindicated due to potentially 
serious CNS toxicity known as serotonin syndrome. 
It has been reported that the combination would result 
in tremors, agitation, restlessness, muscle rigidity, 
and incoordination which was also happened in this 
62-year-old patient. (Richard, Kurlan, Tanner et al, 
1997)  
 
Similar case was also reported by Hinds, Hiller and 
Wiles on 2000. 42-year-old woman presented with 
symptom of confusion, immobility, and tremor on her 
upper limbs. She was diagnosed as Parkinson disease 
patients and has also developed severe depression. 
Her doctor prescribed selegiline 10 mg once daily as 
her anti-parkinson’s agent and nortriptyline 75 mg 
daily as her antidepressant agent. Nortiptyline was 
known to be classified in the same group as 
amitriptyline, which was TCA. A provisional 
diagnosis of serotonin syndrome was made and both 
treatments were stopped. (Hinds, Hillier, Wiles, 
2000) 
 
An algorithm to detected serotonin syndrome has 
been published by Boyer and Shannon, 2005. This 
tool was reported to be 84% sensitive and 97% 
specific to detect serotonine syndrome. The result of 
the analysis was shown on figure 1. Another 
algorithm called the Hunter Serotonin Syndrome 
Criteria was also used was published by Buckley, 
Dawson, and Isbister, 2014. In this research, this 
algorithm was also used to confirmed serotonin 
syndrome in this Indonesian Parkinson patient. The 
algorithm showed more clearly that the patients has a 
potential sign to be stated as a patient with seroto-nin 
syndrome or also known as serotonin toxicity. 
Agitation and tremor which were two symptoms that 
presented in this patient according to the article 
published by Buckley, Dawson and Isbister, 2000 
could be a sign of moderate serotonin syndrome. In 
the article, it was said that if a patient developed 
tremor and agitation, it was indicated that the level of 
serotonin has been risen 5-10 times the normal levels. 
The result of the analysis was summarized in figure 
2.  
 
 
Figure 1.  The analysis result of patient’s condition using sero 
tonin syndrome’s algorithm of Boyer and Shanon, 
2005. It could be concluded that the patient possibly 
developed serotonin syndrome. The yellow boxes 
demonstrated the analysis result. 
  
Figure 2.  The analysis results of patient’s condition  
using Hunter Serotonin Syndrome Criteria. It 
could be concluded from the criteria that this 
patient had a possibility to developed serotonin 
syndrome. The red boxes demonstrated the 
analysis results. (Buckley, Dawson and Isbister, 
2000) 
 
 
Table 4.   Naranjo Scale Result  
 
Naranjo Adverse Drug Reaction Probabillity Scale 
Question Yes No Do Not 
Know 
Score 
1. Are there previous 
conclusive report on 
this reaction 
+1 0 0 +1 
2. Did the adverse event 
appear after the 
suspected drug 
administer? 
+2 +1 0 +2 
3. Did the adverse 
reaction improve when 
the drug was 
discontinued or a 
specific antagonist was 
administered? 
+1 0 0 0 
4. Did the adverse event 
reappear when the drug 
was re-administered 
+2 -1 0 0 
5. Are there alternative 
causes (other than the 
drug) that could on 
their own have caused 
the reaction 
-1 +2 0 +2 
6. Did the reaction 
reappear when placebo 
was given 
-1 +1 0 0 
7. Was the drug detected 
in blood (or other 
fluids) in 
concentrations known 
to be toxic? 
+1 0 0 0 
8. Was the reaction more 
severe when the dose 
was increased or less 
severe when the dose 
was decreased  
+1 0 0 0 
9. Did the patient have a 
similar reaction to the 
same or similar drugs 
in any previous 
exposure? 
+1 0 0 0 
Has a Serotonergicc agent been administered in 
the  past five weeks?
Yes
Are Any of the following Symptomp Present?  
1. Tremor or hyperflexia  2. Spontaneous 
clonus 3. Muscle rigidity and either ocular 
clonus or inducible clonus 4. Ocular clonus 
and either agitation or diaphoresis 5. 
Inducible clonus and either agitation or 
daiphoresis
Yes
Serotonin 
Syndrome
No
Not Serotonine 
Syndrome
No
Not Serotonine 
Syndrome
10. Was the adverse drug 
reaction confirmed by 
any objective 
evidence? 
+1 0 0 +1 
Total Score    +6 
 
Naranjo scale is known as a tool to assess the 
possibility of medication developing adverse drug 
reaction. In this case report, we checked the 
possibility of selegiline in combination with 
amitriptyline developed serotonin syndrome using 
this tool. The calculation of this case report 
demonstrated a total score 6. This total score was in 
the range of 5-8, which meant probable adverse drug 
reaction caused by combination of both drugs. The 
result was presented in table 4. 
 
The Medscape drug interaction checker, literature 
review, algorithm from several scientific articles, and 
Naranjo scale had shown supporting results which 
indicated this 62-year-old man was developing 
serotonine syndrome. According to Buckley, 
Dawson, and Ibster, 2014 Serotonin syndrome in 
moderate cases as predicted in this patient, usually 
resolves in one or three days after stopping the 
serotonergic drugs. It was suggested to both the 
neurologist of hospital B to stop selegiline and 
amitriptyline.  
 
The case report was the pioneer case report of 
serotonin syndrome in Indonesian patient with 
Parkinson disease. This research could be a good 
example to increase the awareness of pharmacist, 
doctor and other health care provider of the 
possibility of serotonin syndrome if selegiline and 
amitriptyline was combined.  
 
The limitations of this case report were this case 
report only consist of one case and was written before 
the monitoring after the intervention was performed. 
It is also suggested to record more cases to record the 
prevalence of serotonin syndrome especially in Indo 
 
nesian patients. Medication screening of Parkinson 
treatment combination should be performed 
continuously by all health care provider, especially 
pharmacist.  
5 CONCLUSION 
Drug related problems (DRP) was found in this case 
report. According to the patients complain, the drug 
related problem was induced by the interaction of 
selegiline and amitriptyline. This interaction was a 
probable cause of an adverse drug reaction called 
serotonin syndrome. This condition has been reported 
in several cases in the form of objective evidence. 
Increasing pharmacist and other health care provider 
awareness about serotonin syndrome in Indonesian 
Parkinson disease patients would be important to 
optimized patient’s clinical outcome.   
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